The University of Southampton
University of Southampton Institutional Repository

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology

CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology
The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity.
0037-1963
107-114
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded

Beers, Stephen A., Chan, H.T. Claude, French, Ruth R., Cragg, Mark S. and Glennie, Martin J. (2010) CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology. Seminars in Hematology, 47 (2), 107-114. (doi:10.1053/j.seminhematol.2010.01.001).

Record type: Article

Abstract

The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity.

Full text not available from this repository.

More information

Published date: April 2010

Identifiers

Local EPrints ID: 148173
URI: http://eprints.soton.ac.uk/id/eprint/148173
ISSN: 0037-1963
PURE UUID: 233764b4-fa50-4cb2-a03d-2ab89ef5e637
ORCID for Mark S. Cragg: ORCID iD orcid.org/0000-0003-2077-089X

Catalogue record

Date deposited: 27 Apr 2010 13:48
Last modified: 03 Dec 2019 01:57

Export record

Altmetrics

Contributors

Author: H.T. Claude Chan
Author: Ruth R. French
Author: Mark S. Cragg ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×